hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06278194, orgStudyIdInfo id: 22.11.2023.589, briefTitle: Masseter Muscle Thickness in Gasser Ganglion Radiofrequency Treatment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-07-15, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Başakşehir Çam & Sakura City Hospital, class: OTHER_GOV, descriptionModule briefSummary: Trigeminal neuralgia is common painful disorder in pain medicine clinics. Gasserian ganglion radiofrequency thermocoagulation is one of the treatment option in patients with trigeminal neuralgia in refractory cases. The most commonly involved branch in trigeminal neuralgia is the mandibular branch. Masseter muscle is innervated by mandibulary nerve branch of the trigeminal nerve.The radiofrequency thermocoagulation therapy is used to ablate the affected trigeminal nerve branch and some of patients complain of subjective masseter weakness after this procedure.In theoretical basis, muscles innervated by target nerve are affected from ablation procedure. In this study the primary aim is to evaluate the change of the masseter muscle thickness in patients treated by gasserian ganglion radiofrequency thermocoagulation. The results may also show possible functional effect of the procedure related with masseter muscle., conditionsModule conditions: Trigeminal Neuralgia, conditions: Gasserian Ganglion; Lesion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Gasserian Ganglion Radiofrequency Thermocoagulation, outcomesModule primaryOutcomes measure: Masseter muscle thickness, primaryOutcomes measure: Masseter muscle thickness, primaryOutcomes measure: Masseter muscle thickness, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06278181, orgStudyIdInfo id: 2023/08/1545, briefTitle: Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-21, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-01-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, collaborators name: University of Dschang, collaborators name: European Foundation for the Study of Diabetes, descriptionModule briefSummary: Non-communicable diseases (NCDs) such as diabetes are increasing in countries where malaria transmission is common. This study aims to investigate the relationship between NCDs and parasitic infections in Cameroon. The investigators will assess the risk of malaria, as well as other parasitic diseases, in a prospectively followed group of adults with diabetes, compared with those without diabetes. Malaria parasites and intestinal worms will be tested using blood and stool collected at four time points during a one-year follow-up. In addition, this project will investigate how natural protection against malaria is affected by diabetes and other risk factors for heart diseases., conditionsModule conditions: Malaria, conditions: Diabetes Mellitus, conditions: Metabolic Syndrome, conditions: Endemic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: asymptomatic malaria, secondaryOutcomes measure: symptomatic malaria, otherOutcomes measure: schistosoma infection, otherOutcomes measure: strongyloides infection, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Limbe Regional Hospital, status: RECRUITING, city: Limbe, country: Cameroon, contacts name: George Awungafac, MD, role: CONTACT, phone: +23779750125, email: george.awungafac@ki.se, geoPoint lat: 4.02356, lon: 9.20608, hasResults: False
protocolSection identificationModule nctId: NCT06278142, orgStudyIdInfo id: ERTELEME_1, briefTitle: Web-Based Cognitive Behavior Therapy for Procrastination, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Anadolu University, class: OTHER, descriptionModule briefSummary: The main purpose of this study is to present the development process and project flow of an internet-based self-help intervention programme to reduce the level of procrastination among university students., conditionsModule conditions: Mental Health Issue, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Internet Based Intervention - GUIDED, interventions name: Internet Based Intervention - WİTHOUT GUİDANCE, outcomesModule primaryOutcomes measure: Tuckman Procrastination Behaviour Scale, primaryOutcomes measure: Cognitive Distortions Questionnaire, primaryOutcomes measure: Time Management Scale, primaryOutcomes measure: Attitude Scale for Internet-Based Interventions, secondaryOutcomes measure: Depression Anxiety Stress Scale-21 (DASS-21), otherOutcomes measure: Sociodemographic Information Form, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06278129, orgStudyIdInfo id: 4146, briefTitle: Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière's Disease, acronym: MRI_SSHL/MD, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-06-19, primaryCompletionDateStruct date: 2021-04-23, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, class: OTHER, descriptionModule briefSummary: Evaluation of the diagnostic and prognostic efficacy of nuclear magnetic resonance imaging in patients with acute sensorineural hearing loss or in patients suffering from probable or definite MD. The neuroradiological and audiological evaluation are held on in the same day in order to better clarify the radiological and clinical correlates., conditionsModule conditions: Sudden Sensorineural Hearing Loss, conditions: Meniere Disease, conditions: Ménière's Vertigo, conditions: Meniere's Disease Aggravated, conditions: Inner Ear Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Vestibular myogenic potentials, outcomesModule primaryOutcomes measure: Evaluation of inner ear structures in MRI images, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Audiology and Neuroradiology - Milan (Italy), status: RECRUITING, city: Milan, zip: 20133, country: Italy, contacts name: Diego Zanetti, MD Prof, role: CONTACT, phone: 00390255033936, email: audiologia@policlinico.mi.it, contacts name: Federica Di Berardino, MD Prof, role: PRINCIPAL_INVESTIGATOR, contacts name: Giorgio Conte, MD Prof, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06278116, orgStudyIdInfo id: 2024-ALIGNERSCLEANSIGN, briefTitle: Comparison of Absorbance Values, Sensory Evaluations and Periodontal Effects of Five Different Products for Clean Aligners Cleansing, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Pavia, class: OTHER, descriptionModule briefSummary: The aim of the study is to evaluate the most efficient product for the cleaning of Invisalign® clear aligners (Align Technology Inc., San Jose, CA, USA) through objective and subjective assessments after the use of 5 different products. For each aligner, one product is used for 2 weeks until all of them are used, therefore 5 different aligners are required for the study. A periodontal evaluation is conducted to assess variations during the time frame of the study., conditionsModule conditions: Dental Malocclusion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Aligners cleansing with water, interventions name: Aligners cleansing with dish soap Svelto, interventions name: Aligners cleansing with Polident Antibacterial Denture Cleaner, interventions name: Aligners cleansing with Invisalign Cleaning Crystals, interventions name: Aligners cleansing with Geldis, outcomesModule primaryOutcomes measure: Change in adsorbance (A) value, primaryOutcomes measure: Changes in patient's perception, secondaryOutcomes measure: Changes in Probing Pocket Depth (PPD) values, secondaryOutcomes measure: Changes in Gingival Index (GI) values, secondaryOutcomes measure: Changes in Bleeding on probing (BOP), secondaryOutcomes measure: Change in Schiff Air Index - Dental sensitivity test, secondaryOutcomes measure: Change of the BEWE Index Basic Erosive Wear Examination, secondaryOutcomes measure: Change in plaque index (PI):, eligibilityModule sex: ALL, minimumAge: 14 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia, status: RECRUITING, city: Pavia, state: Lombardy, zip: 27100, country: Italy, contacts name: Andrea Scribante, DDS, PhD, role: CONTACT, phone: +39 0382516223, email: andrea.scribante@unipv.it, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06278103, orgStudyIdInfo id: 2023PI113, briefTitle: Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas (MethylRH-M), acronym: MethylRH-M, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2000-01-01, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Central Hospital, Nancy, France, class: OTHER, descriptionModule briefSummary: This research aims to explore the relationship between hormonal receptor expression and the clinical and histopathological characteristics of meningiomas. The underlying hypothesis is that hormonal receptor expression, as well as the methylation profile of their gene promoters, are associated with specific aspects of meningiomas and patients' clinical outcomes. The main objective is to study the correlation between the immunohistochemical expression of hormonal receptors and clinicopathological data. The secondary objectif is to study the correlation between the methylation profile of hormonal receptor gene promoters and their immunohistochemical expression., conditionsModule conditions: Meningioma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 180, type: ESTIMATED, outcomesModule primaryOutcomes measure: immunohistochemical expression of different hormonal receptors, secondaryOutcomes measure: methylation profile of the promoters of hormonal receptor genes, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06278090, orgStudyIdInfo id: AUDC, briefTitle: Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution, acronym: GALPOL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2026-02, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about the impact of ursodeoxycholic acid treatment on the gallbladder polyp evolution in patients with gallbladder polyps that undergo follow up. The main question it aims to answer is:• Whether ursodeoxycholic acid could decrease the gallbladder polyp size and therefore spare unnecessary follow up or surgical interventionsParticipants will be managed according to the standard practice of the department they are attended:* According to the established practice in the Department of Surgery, patients that either do not have an indication for cholecystectomy or decline the offered intervention, and are subjects for a follow up, are usually prescribed Ursodeoxycholic Acid, at 10-15 mg/kg/day for at least 6 months.* According to the standard practice of Gastroenterology Department, patients are followed up according to the published guidelines.Researchers will compare the groups that receive or not ursodeoxycolic acid treatment to see if the polyp size evolution differs significantly., conditionsModule conditions: Gallbladder Polyp, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Ursodeoxycholic Acid Only Product, outcomesModule primaryOutcomes measure: Reducing gallbladder polyp size by 2mm or more, secondaryOutcomes measure: Modification of the expected follow up, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06278064, orgStudyIdInfo id: BFHHZML20240006, briefTitle: Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Beijing Friendship Hospital, class: OTHER, descriptionModule briefSummary: This study constitutes a case-control investigation employing a retrospective approach. Plasma samples from individuals with esophageal cancer, benign esophageal diseases, gastric cancer, benign gastric diseases, and a healthy control group were systematically collected. Advanced Data-Independent Acquisition (DIA) proteomics and single-vesicle membrane protein detection techniques were employed to quantify protein content within exosomes. Specific protein biomarkers indicative of early-stage upper gastrointestinal tumors were identified. External validation of these protein markers was conducted using Parallel Reaction Monitoring (PRM) technology on an independent validation cohort. The objective is to establish protein marker predictions for early diagnosis of upper gastrointestinal tumors and prognostication of therapeutic efficacy., conditionsModule conditions: Gastric Cancer, conditions: Esophagus Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 562, type: ESTIMATED, armsInterventionsModule interventions name: Gastric Cancer, interventions name: Esophagus Cancer, outcomesModule primaryOutcomes measure: Plasma proteins in patients with gastric cancer, primaryOutcomes measure: Plasma proteins in patients with esophagus cancer, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Fourth Hospital of Hebei Medical University, status: RECRUITING, city: Shijiazhuang, state: Hebei, country: China, contacts name: Lianmei Zhao, Ph.D., role: CONTACT, geoPoint lat: 38.04139, lon: 114.47861, locations facility: Beijing Friendship Hospital, Capital Medical University, status: RECRUITING, city: Beijing, country: China, contacts name: Li Min, Ph.D., role: CONTACT, contacts name: Li Min, Ph.D, role: PRINCIPAL_INVESTIGATOR, contacts name: Chenjie Xu, Ph.D, role: SUB_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Cancer Hospital Chinese Academy of Medical Sciences, status: RECRUITING, city: Beijing, country: China, contacts name: Yibin Xie, Ph.D, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06278012, orgStudyIdInfo id: E-59394181-604.01.02-32288, briefTitle: Development of Atılım Kinesiophobia Scale, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-03-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Atılım University, class: OTHER, descriptionModule briefSummary: Background:Kinesiophobia or fear of movement, is defined as an excessive and irrational fear of physical movement to avoid painful injury, harm or re-injury. The existing scales measuring kinesiophobia are thought to have some limitations (the difficulty of patients to understand and answer the questions, the presence of questions that are not suitable for the patient's condition). These questionnaires may not have specific questions enough to assess fear of movement in different patient populations.Aim: The aim of this study is to develop and validate the Turkish Atılım Kinesiophobia Scale.Material/method:In the first stage of the study, research on kinesiophobia was reviewed and a total of 38 questions were created for the scale. The questions were submitted to the opinion of 11 experts working in the physiotherapy and rehabilitation field. Then A total of 100 patients with acute and chronic musculoskeletal pain completed the Turkish Atılım Kinesiophobia Scale and Tampa Scale of Kinesiophobia., conditionsModule conditions: Kinesiophobia, conditions: Acute Pain, conditions: Chronic Pain, conditions: Fear of Movement, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 150, type: ESTIMATED, outcomesModule primaryOutcomes measure: The pilot study of the scale will be conducted with a total of 40 patients, 10 participants for each patient group., primaryOutcomes measure: item analyses and exploratory factor analysis (EFA) analysis will be performed with a sample size of 5 times the number of questions in the item pool with acute and chronic pain patients., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Atılım University, status: RECRUITING, city: Ankara, country: Turkey, contacts name: Naime Uluğ, PhD., role: CONTACT, phone: +905365434409, email: naime.ulug@atilim.edu.tr, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06277999, orgStudyIdInfo id: D8820C00001, briefTitle: C.Difficile Observational Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-10-11, completionDateStruct date: 2024-10-11, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: AstraZeneca, class: INDUSTRY, descriptionModule briefSummary: D8820C00001 is an exploratory, non-interventional, unblinded, observational study evaluating the acceptability, feasibility and performance of methods to collect, transport and test biospecimens in participants ≥ 18 years of age with an active CDI. Participants will also be monitored for recurring episodes of diarrhea and will need to complete validated PROs and study evaluation questionnaires, conditionsModule conditions: Clostridium Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Number of participants that completed key study activities according to protocol, secondaryOutcomes measure: Time intervals across stool sample collection logistics, secondaryOutcomes measure: Participant Experience and site staff evaluation questionnaires, secondaryOutcomes measure: Gather information to assess logistics, resourcing and performance of different toxin detection assays (eg. EIA, PCR, CCNA), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 130 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06277986, orgStudyIdInfo id: KY20212018-F-2, briefTitle: Early Diagnosis of Gastric Cancer Cachexia, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-06-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Xijing Hospital, class: OTHER, descriptionModule briefSummary: Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia., conditionsModule conditions: Cachexia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: cachexia, outcomesModule primaryOutcomes measure: BMI, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fourth Military Medical University, status: RECRUITING, city: Xi'an, state: Shaanxi, country: China, contacts name: Jipeng Li, role: CONTACT, phone: +86-029-84771533, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False